IHC - CD20

A positive result indicates the presence of CD20 proteins on cells in the tested tissue. This is often indicative of a B-cell lymphoma, but your doctor will interpret your results in the context of your symptoms and other test results.

The risks or side effects are typically associated with the procedure to obtain the tissue sample, such as a biopsy, and not the test itself. Your healthcare provider will discuss these risks with you prior to the procedure.

The tissue sample is usually obtained through a biopsy procedure, which involves extracting a small sample of tissue for examination under a microscope.

No, the IHC - CD20 test requires a tissue sample that needs to be collected by a healthcare professional and analyzed in a laboratory.

The turnaround time for results is typically 3-5 days but may vary depending on the laboratory.

Yes, this test can be repeated to evaluate the response to treatment in certain types of B-cell lymphomas.

The IHC - CD20 test is often performed as part of a panel of tests to diagnose and classify lymphomas. Other tests may include additional immunohistochemistry tests, flow cytometry, or genetic tests, depending on the suspected type of lymphoma.

While a positive result can be indicative of B-cell lymphoma, this test is typically used in conjunction with other diagnostic tests and clinical information to make a definitive diagnosis.

No specific preparation is needed for the IHC - CD20 test. However, it's important to discuss any medications or supplements you're taking with your healthcare provider as they might interfere with the results.

The IHC - CD20 test is considered highly reliable and specific for detecting B-cell lymphomas, however, its accuracy is also dependent on the quality of the sample and the expertise of the pathology team.

A negative result means that the CD20 protein was not detected in the sample. This could suggest that the lymphoma, if present, is not of B-cell origin or is a type of B-cell lymphoma that doesn't express CD20.

The presence or absence of CD20 can have therapeutic implications since anti-CD20 monoclonal antibodies are an effective treatment for many B-cell lymphomas. However, the test itself does not provide direct prognostic information.

The IHC - CD20 test is usually performed on a tissue sample obtained through a biopsy. It is not typically done on a blood sample.

While the test can confirm the presence of B cells, it is not used alone to differentiate between various types of B-cell lymphomas. Other tests, including additional IHC markers and genetic tests, are used for this purpose.

Yes, testing for CD20 can be helpful in monitoring the effectiveness of treatments like rituximab, an anti-CD20 monoclonal antibody, in certain types of B-cell lymphomas.

If the test is inconclusive, your healthcare provider may recommend repeating the test or performing additional tests to assist in making a diagnosis.

While its primary use is in the diagnosis of B-cell lymphomas, the IHC - CD20 test can also be used in research settings or in diagnosing other less common conditions.

Test results should be interpreted by a healthcare provider who will consider the test results in the context of your overall clinical picture and other diagnostic tests.

Yes, there are no dietary restrictions before the test as it does not require a blood sample. However, certain medications and supplements may need to be avoided, so discuss these with your healthcare provider.